Cite
HARVARD Citation
D'Haens, G. et al. (n.d.). P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study. Journal of Crohn's and colitis. pp. S416-S417. [Online].